Skip to main content

Is developing an HIV-1 vaccine possible?

Publication ,  Journal Article
Haynes, BF; Liao, H-X; Tomaras, GD
Published in: Curr Opin HIV AIDS
September 2010

PURPOSE OF REVIEW: This review discusses select recent data that suggest that indeed it is possible to make a clinically useful preventive vaccine for HIV-1 and outlines some of the remaining obstacles that stand in the way of success. RECENT FINDINGS: Passive protection studies, with broad neutralizing antibodies for mucosal simian-HIV challenges, in nonhuman primates have suggested that lower doses of neutralizing antibodies than previously thought may be effective in preventing HIV-1 infection. The use of recombinant antibody technology coupled with the ability to culture single memory B cells has yielded new broad neutralizing antibodies and new targets for vaccine design. The success of the RV144 Thai HIV-1 efficacy trials with a replication-defective recombinant canarypox vector (ALVAC)/gp120 prime, clade B/E recombinant gp120 protein boost showing 31% efficacy has given hope that indeed a protective HIV-1 vaccine can be made. SUMMARY: Recent data in the last year have provided new hope that a clinically useful preventive HIV-1 vaccine can potentially be made. The path forward will require development of improved immunogens, understanding the correlates of protection to HIV-1, and development of immunogens to induce antibodies that can prevent the initial stages of HIV-1 infection at mucosal sites, in order to improve on the RV144 trial results.

Duke Scholars

Published In

Curr Opin HIV AIDS

DOI

EISSN

1746-6318

Publication Date

September 2010

Volume

5

Issue

5

Start / End Page

362 / 367

Location

United States

Related Subject Headings

  • Virology
  • Vaccination
  • Simian Acquired Immunodeficiency Syndrome
  • Humans
  • HIV-1
  • HIV Infections
  • Disease Models, Animal
  • Clinical Trials as Topic
  • Antibodies, Neutralizing
  • Animals
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Haynes, B. F., Liao, H.-X., & Tomaras, G. D. (2010). Is developing an HIV-1 vaccine possible? Curr Opin HIV AIDS, 5(5), 362–367. https://doi.org/10.1097/COH.0b013e32833d2e90
Haynes, Barton F., Hua-Xin Liao, and Georgia D. Tomaras. “Is developing an HIV-1 vaccine possible?Curr Opin HIV AIDS 5, no. 5 (September 2010): 362–67. https://doi.org/10.1097/COH.0b013e32833d2e90.
Haynes BF, Liao H-X, Tomaras GD. Is developing an HIV-1 vaccine possible? Curr Opin HIV AIDS. 2010 Sep;5(5):362–7.
Haynes, Barton F., et al. “Is developing an HIV-1 vaccine possible?Curr Opin HIV AIDS, vol. 5, no. 5, Sept. 2010, pp. 362–67. Pubmed, doi:10.1097/COH.0b013e32833d2e90.
Haynes BF, Liao H-X, Tomaras GD. Is developing an HIV-1 vaccine possible? Curr Opin HIV AIDS. 2010 Sep;5(5):362–367.

Published In

Curr Opin HIV AIDS

DOI

EISSN

1746-6318

Publication Date

September 2010

Volume

5

Issue

5

Start / End Page

362 / 367

Location

United States

Related Subject Headings

  • Virology
  • Vaccination
  • Simian Acquired Immunodeficiency Syndrome
  • Humans
  • HIV-1
  • HIV Infections
  • Disease Models, Animal
  • Clinical Trials as Topic
  • Antibodies, Neutralizing
  • Animals